Mirion Technologies, Inc. Class A (MIR)

Over the past six months, Mirion Technologies, Inc. stock has decreased by 19.0% to approximately $18.97 as of May 9, 2026. Key events impacting the stock price include the Q4 2025 financial results and 2026 guidance, the acquisition of Paragon Energy Solutions, the Q1 2026 financial results, and analyst sentiment. Mirion reported a 9% increase in fourth-quarter sales and a 7% increase in full-year sales for 2025. The acquisition of Paragon Energy Solutions strengthens Mirion's positioning in the Small Modular Reactor (SMR) market. In Q1 2026, revenue was up 27.5% year-over-year, and adjusted EPS was $0.10, but the company reported a GAAP net loss of US$3.4 million. As of May 2026, Mirion Technologies has a consensus rating of 'Moderate Buy' from analysts.

Explicit information detailing specific seasonal patterns for Mirion Technologies, Inc.'s products and services is not readily available. Demand is driven by recurring expenditures from defense customers, upgrades and replacements in laboratories and research markets, and the use of Mirion's QA solutions by global cancer centers. New construction and modernization of facilities, rising global nuclear capacity and medical imaging demand, and increased healthcare investment also drive demand. Geopolitical events reinforce the need for secure baseload energy, further contributing to demand in the nuclear power sector.

Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions, operating within the Industrials sector. The company operates through two segments: the Medical Segment, which focuses on improving cancer care quality and safety, and the Nuclear & Safety Segment, which drives advancements in nuclear energy and provides radiation safety applications. Major products include the InstadoseVUE wireless dosimeter, AB-100 Module, and TELE-GMP Telescopic Pole.

Mirion Technologies, Inc. has a global presence with approximately 2,800 employees and operations in 12 countries across North America, Europe, and Asia, including the United States, Canada, the United Kingdom, Germany, France, Belgium, Finland, China, Japan, and South Korea. The company's global footprint is supported by a network of suppliers and distributors.

Mirion Technologies maintains a strong brand reputation as a trusted global provider of safety technology. The company continues to launch advanced products, demonstrating ongoing innovation in radiation detection and safety solutions. Mirion's active participation in prominent events showcases its engagement with key industry stakeholders. Mirion Crew Active Dosimeters were selected to be worn by astronauts on NASA's Artemis II Mission. Mirion was selected as an official partner for World Engineering Day for Sustainable Development 2026. The company's Mirion Medical group is dedicated to improving quality in cancer care.

Mirion Technologies' ownership is primarily held by institutional investors. As of December 2025, 353 institutional investors held 100.1% of outstanding shares, while by May 2026, institutional ownership was reported at 78.51%. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., and T. Rowe Price Investment Management, Inc. Individual investors hold approximately 5.45% of the shares. Thomas D. Logan has served as CEO since 2005 and became Chairman of the Board in February 2025.